Management holds an investor webinar highlighting the potential for Fosgonimeton to protect and preserve neuronal health in mild-to-moderate Alzheimer’ Disease patients on June 18 at 11:30 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHA:
- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
- Athira Pharma to host webinar highlighting potential for fosgonimeton
- Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma completes first cohort in Phase 1 trial of ATH-1105
- Athira Pharma to Participate in Upcoming June Conferences